What is Letrozole?
Letrozole is a nonsteroidal aromatase inhibitor (AI) that blocks the conversion of androgens to estrogens, primarily used in postmenopausal women with hormone receptor-positive breast cancer. 1
Mechanism of Action
Letrozole works by competitively binding to the heme of the cytochrome P450 subunit of the aromatase enzyme, which normally converts adrenal androgens (androstenedione and testosterone) to estrone and estradiol in postmenopausal women. 1 By inhibiting this enzyme, letrozole:
- Suppresses plasma estrogen levels by 75-95% within 2-3 days of treatment initiation 1
- Reduces serum estrone, estradiol, and estrone sulfate concentrations
- Does not impair adrenal steroidogenesis or affect cortisol, aldosterone, thyroid function, or androgen levels 1
- Selectively targets gonadal steroidogenesis without affecting mineralocorticoid or glucocorticoid synthesis
This mechanism makes letrozole highly specific for estrogen suppression without the broader endocrine effects seen with other hormonal therapies.
Clinical Applications
Primary Use: Breast Cancer Treatment
Letrozole is FDA-approved and guideline-recommended for hormone receptor-positive breast cancer in postmenopausal women across multiple settings:
Adjuvant therapy: Used after primary breast cancer treatment to reduce recurrence risk 2
Extended adjuvant therapy: The standard dose is 2.5 mg daily, studied extensively in trials like MA.17R and NSABP B-42, where letrozole was given for an additional 5 years after completing initial endocrine therapy (4.5-6 years of AI therapy, often preceded by tamoxifen). 2 This extended treatment improved disease-free survival (95% vs 91% at 5 years, HR 0.79, p=0.048) and reduced contralateral breast cancer risk (HR 0.66-0.72). 2
Metastatic disease: Combined with CDK4/6 inhibitors (like palbociclib) as first-line treatment in postmenopausal women with HR-positive, HER2-negative metastatic breast cancer, significantly improving progression-free survival (27.6 months vs 14.5 months with letrozole alone). 3
Off-Label Use: Ovulation Induction
Letrozole is increasingly used as a first-line agent for ovulation induction in women with polycystic ovary syndrome (PCOS), showing better pregnancy and live birth rates compared to clomiphene citrate, particularly in CC-resistant cases. 4, 5, 6 Unlike clomiphene, letrozole does not deplete estrogen receptors, avoiding antiestrogenic effects on endometrium and cervical mucus. 5
Emerging Applications
Recent evidence suggests potential utility in ectopic pregnancy management as a fertility-preserving alternative to methotrexate, with success rates of 74.7-90.5% depending on dosing regimen. 7, 8
Adverse Effects Profile
Common Side Effects
The most frequently reported adverse events from large trials include: 2
- Musculoskeletal symptoms: Arthralgia (50-69%), arthritis (30-33%), myalgia (25-37%)
- Vasomotor symptoms: Hot flashes (38-54%)
- Fatigue: (36-45%)
- Bone-related effects: New osteoporosis (11% vs 6% placebo, p<0.001), increased fracture risk (14% vs 9% placebo, p=0.001) 2
Serious Adverse Events
A meta-analysis of extended AI therapy demonstrated increased risk of: 2
- Bone fractures: OR 1.34 (95% CI 1.16-1.55), number needed to harm = 72
- Cardiovascular events: OR 1.18 (95% CI 1.00-1.40), number needed to harm = 122
- Treatment discontinuation due to adverse events: OR 1.45 (95% CI 1.25-1.68), number needed to harm = 21
Critical caveat: While bone fracture risk increases, letrozole does not affect overall survival or increase risk of second malignancies or non-breast cancer deaths. 2
Rare but serious: Reversible acute heart failure has been reported, requiring immediate discontinuation and cardiology consultation. 9
Pharmacokinetics
- Absorption: Rapid and complete from GI tract, unaffected by food 1
- Standard dose: 2.5 mg daily orally
- Metabolism: Slowly metabolized to inactive metabolite, excreted renally (90% in urine) 1
- Maximal estrogen suppression: Achieved within 2-3 days 1
Quality of Life Considerations
In the MA.17R trial, letrozole maintained overall health-related quality of life with no significant differences in most SF-36 or MENQOL subscale scores compared to placebo, though the role-physical subscale showed worse scores (p=0.009). 2 Intermittent dosing schedules showed less worsening in physical well-being, mood, and sleep disturbances compared to continuous therapy. 2
Key Clinical Pearls
- No need for glucocorticoid or mineralocorticoid supplementation as letrozole does not impair adrenal function 1
- Monitor bone health: Consider baseline and periodic bone density assessments given increased fracture risk
- Cardiovascular vigilance: Educate patients about cardiac symptoms and maintain low threshold for cardiology referral 9
- Fertility preservation: Unlike methotrexate, letrozole shows no observed detriment to ovarian reserve (AMH levels unchanged) 8
- Drug interactions: Letrozole is highly specific with minimal systemic effects beyond estrogen suppression 1